Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

被引：6

作者：

Matsumoto, Kinnosuke ^{[1
]}

Shiroyama, Takayuki ^{[1
]}

Tamiya, Motohiro ^{[2
]}

Minami, Toshiyuki ^{[3
]}

Kinehara, Yuhei ^{[4
]}

Tamiya, Akihiro ^{[5
]}

Suga, Yasuhiko ^{[6
]}

Kuge, Tomoki ^{[1
,7
]}

Mori, Masahide ^{[7
]}

Suzuki, Hidekazu ^{[8
]}

Tobita, Satoshi ^{[9
]}

Ueno, Kiyonobu ^{[9
]}

Namba, Yoshinobu ^{[10
]}

Tetsumoto, Satoshi ^{[11
]}

Niki, Toshie ^{[12
]}

Morimura, Osamu ^{[13
]}

Osa, Akio ^{[14
]}

Nishino, Kazumi ^{[2
]}

Nagatomo, Izumi ^{[1
]}

Takeda, Yoshito ^{[1
]}

Kijima, Takashi ^{[3
]}

Kumanogoh, Atsushi ^{[1
,15
,16
,17
,18
,19
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

[2] Osaka Int Canc Inst, Dept Resp Med, Osaka, Japan

[3] Hyogo Med Univ, Dept Resp Med & Hematol, Hyogo, Japan

[4] Nippon Life Hosp, Dept Resp Med & Clin Immunol, Osaka, Japan

[5] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Internal Med, Osaka, Japan

[6] Osaka Police Hosp, Dept Resp Med, Osaka, Japan

[7] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Osaka, Japan

[8] Osaka Habikino Med Ctr, Dept Thorac Oncol, Osaka, Japan

[9] Osaka Gen Med Ctr, Dept Resp Med, Osaka, Japan

[10] Takarazuka City Hosp, Dept Resp Med, Hyogo, Japan

[11] Suita Municipal Hosp, Dept Resp Med & Clin Immunol, Osaka, Japan

[12] Nishinomiya Municipal Cent Hosp, Dept Resp Med, Hyogo, Japan

[13] Toyonaka City Hosp, Dept Resp Med, Osaka, Japan

[14] Kinki Cent Hosp, Dept Resp Med, Hyogo, Japan

[15] Osaka Univ, Immunol Frontier Res Ctr iFReC, Dept Immunopathol, World Premier Int WPI, Osaka, Japan

[16] Osaka Univ, Inst Open & Transdisciplinary Res Initiat OTRI, Integrated Frontier Res Med Sci Div, Osaka, Japan

[17] Osaka Univ, Ctr Infect Dis Educ & Res CiDER, Suita, Osaka, Japan

[18] Osaka Univ, Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol AMED CREST, Suita, Osaka, Japan

[19] Osaka Univ, Ctr Adv Modal & DDS CAMaD, Osaka, Japan

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2024年 / 73卷 / 01期

关键词：

Nivolumab; Ipilimumab; Pembrolizumab; Non-small-cell Lung cancer; Propensity score; Real-world; CHECKMATE; 9LA; NSCLC; COMBINATION; UPDATE;

D O I：

10.1007/s00262-023-03583-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IntroductionNivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). Compared with immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy can increase immune-related toxicity instead of prolonging survival. This study aimed to compare the efficacy and safety of NICT and PCT to decide on the favorable treatment.MethodsWe conducted a multi-center retrospective cohort study on patients who underwent NICT or PCT between December 2018 and May 2022. Propensity score matching (PSM) was performed with the variables age, sex, smoking status, performance status, stage, histology, and programmed cell death ligand-1 (PD-L1). The Kaplan-Meier method was used to compare survival for the matched patients.ResultsSix hundred consecutive patients were included. After PSM, 81 and 162 patients were enrolled in the NICT and PCT groups, respectively. The baseline characteristics were well-balanced. The median progression-free survival was equivalent (11.6 vs. 7.4 months; P = 0.582); however, the median overall survival (OS) was significantly longer in the NICT group than in the PCT group (26.0 vs. 16.8 months; P = 0.005). Furthermore, OS was better in PD-L1-negative patients who underwent NICT than in those who underwent PCT (26.0 vs. 16.8 months; P = 0.045). Safety profiles did not differ significantly in terms of severe adverse event and treatment-related death rates (P = 0.560, and 0.722, respectively).ConclusionsReal-world data suggests that NICT could be a favorable treatment option compared with PCT for patients with advanced NSCLC. Further follow-up is needed to determine the long-term prognostic benefit.

引用

页数：10

共 31 条

[31] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J].

West, Howard ;

McCleod, Michael ;

Hussein, Maen ;

Morabito, Alessandro ;

Rittmeyer, Achim ;

Conter, Henry J. ;

Kopp, Hans-Georg ;

Daniel, Davey ;

McCune, Steven ;

Mekhail, Tarek ;

Zer, Alona ;

Reinmuth, Niels ;

Sadiq, Ahad ;

Sandler, Alan ;

Lin, Wei ;

Lohmann, Tania Ochi ;

Archer, Venice ;

Wang, Lijia ;

Kowanetz, Marcin ;

Cappuzzo, Federico .

LANCET ONCOLOGY, 2019, 20 (07) :924-937

← 1 2 3 4 →